Immunogenicity and safety of trivalent inactivated influenza vaccine: A randomized, double-blind, multi-center, phase 3 clinical trial in a vaccine-limited country

Journal of Korean Medical Science

Volumn 26, Issue 2, 2011, Pages 191-195

  Song, Joon Young ^a   Cheong, Hee Jin ^a   Woo, Heung Jeong ^b   Wie, Seong Heon ^c   Lee, Jin Soo ^d   Chung, Moon Hyun ^d   Kim, Yang Ree ^e   Jung, Sook In ^f   Park, Kyung Hwa ^f   Kim, Tae Hyong ^g   Uh, Soo Taek ^g   Kim, Woo Joo ^a  

^a Korea University College of Medicine   (South Korea)

^b Hallym University College of Medicine   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Inha University School of Medicine   (South Korea)

^e Uijeongbu St Mary's Hospital   (South Korea)

^f Chonnam National University Medical School   (South Korea)

^g Soonchunhyang University College of Medicine   (South Korea)

Author keywords

Human; Inactivated; Influenza; Influenza Vaccines; Vaccines

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; IMMUNOLOGY; INFLUENZA; MALE; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SOUTH KOREA; VACCINATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; REPUBLIC OF KOREA; VACCINATION; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 79551679046     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2011.26.2.191     Document Type: Article

References (11)

1. Wilschut JC, McElhaney J, Palache B. Influenza. 2nd ed. Philadelphia, PA: Elsevier Ltd 2006; 117-32.
2. Park SC, Choeng HJ, Sohn JW, Choi SJ, Eom JS, Woo HJ, Chun BC, Kim WJ. Efficacy of influenza vaccination among chronic ill patients: retrospective case control study. Infect Chemother 2004; 36: 207-12.
3. Lee JS, Shin KC, Na BK, Lee JY, Kang C, Kim JH, Park O, Jeong EK, Lee JK, Kwon JW, Park SC, Kim WJ. Influenza surveillance in Korea: establishment and first results of an epidemiological and virological surveillance scheme. Epidemiol Infect 2007; 135: 1117-23.
4. Kee SY, Lee JS, Cheong HJ, Chun BC, Song JY, Choi WS, Jo YM, Seo YB, Kim WJ Influenza vaccine coverage rates and perceptions on vaccination in South Korea. J Infect 2007; 55: 273-81.
5. Song JY, Cheong HJ, Hwang IS, Choi WS, Jo YM, Park DW, Cho GJ, Hwang TG, Kim WJ. Long-term immunogenicity of influenza vaccine among the elderly: Risk factors for poor immune response and persistence. Vaccine 2010; 28: 3929-35.
6. European Committee for Proprietary Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96). London, UK: The Europen Agency for the Evaluation of Medicinal Products; c1997 Available at http://www.ema.europa.eu/pdfs/human/bwp/021496en.pdf [accessed on 17 Aug 2010].
7. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of trivalent inactivated influenza vaccines; c2006 Available at http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091985.pdf [accessed on 17 Aug 2010].
8. U.S. Department of Health and Human Services FDA, Center for Biologics Evaluation and Research. Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. 2007. Available at http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRe [accessed on 17 Aug 2010].
9. El Sahly HM, Keitel WA. Clinical data on Fluarix: an inactivated split seasonal influenza vaccine. Expert Rev Vaccines 2008; 7: 713-9.
10. Fedson DS. Pandemic influenza and the global vaccine supply. Clin Infect Dis 2003; 36: 1552-61.
11. Cheong HJ. Safety of influenza vaccine. J Korean Med Assoc 2007; 50: 267-73.